Cargando…
Nanoparticulate Transport of Oximes over an In Vitro Blood-Brain Barrier Model
BACKGROUND: Due to the use of organophosphates (OP) as pesticides and the availability of OP-type nerve agents, an effective medical treatment for OP poisonings is still a challenging problem. The acute toxicity of an OP poisoning is mainly due to the inhibition of acetylcholinesterase (AChE) in the...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2997055/ https://www.ncbi.nlm.nih.gov/pubmed/21151975 http://dx.doi.org/10.1371/journal.pone.0014213 |
_version_ | 1782193261427818496 |
---|---|
author | Wagner, Sylvia Kufleitner, Jürgen Zensi, Anja Dadparvar, Miriam Wien, Sascha Bungert, Judith Vogel, Tikva Worek, Franz Kreuter, Jörg von Briesen, Hagen |
author_facet | Wagner, Sylvia Kufleitner, Jürgen Zensi, Anja Dadparvar, Miriam Wien, Sascha Bungert, Judith Vogel, Tikva Worek, Franz Kreuter, Jörg von Briesen, Hagen |
author_sort | Wagner, Sylvia |
collection | PubMed |
description | BACKGROUND: Due to the use of organophosphates (OP) as pesticides and the availability of OP-type nerve agents, an effective medical treatment for OP poisonings is still a challenging problem. The acute toxicity of an OP poisoning is mainly due to the inhibition of acetylcholinesterase (AChE) in the peripheral and central nervous systems (CNS). This results in an increase in the synaptic concentration of the neurotransmitter acetylcholine, overstimulation of cholinergic receptors and disorder of numerous body functions up to death. The standard treatment of OP poisoning includes a combination of a muscarinic antagonist and an AChE reactivator (oxime). However, these oximes can not cross the blood-brain barrier (BBB) sufficiently. Therefore, new strategies are needed to transport oximes over the BBB. METHODOLOGY/PRINCIPAL FINDINGS: In this study, we combined different oximes (obidoxime dichloride and two different HI 6 salts, HI 6 dichloride monohydrate and HI 6 dimethanesulfonate) with human serum albumin nanoparticles and could show an oxime transport over an in vitro BBB model. In general, the nanoparticulate transported oximes achieved a better reactivation of OP-inhibited AChE than free oximes. CONCLUSIONS/SIGNIFICANCE: With these nanoparticles, for the first time, a tool exists that could enable a transport of oximes over the BBB. This is very important for survival after severe OP intoxication. Therefore, these nanoparticulate formulations are promising formulations for the treatment of the peripheral and the CNS after OP poisoning. |
format | Text |
id | pubmed-2997055 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2010 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-29970552010-12-10 Nanoparticulate Transport of Oximes over an In Vitro Blood-Brain Barrier Model Wagner, Sylvia Kufleitner, Jürgen Zensi, Anja Dadparvar, Miriam Wien, Sascha Bungert, Judith Vogel, Tikva Worek, Franz Kreuter, Jörg von Briesen, Hagen PLoS One Research Article BACKGROUND: Due to the use of organophosphates (OP) as pesticides and the availability of OP-type nerve agents, an effective medical treatment for OP poisonings is still a challenging problem. The acute toxicity of an OP poisoning is mainly due to the inhibition of acetylcholinesterase (AChE) in the peripheral and central nervous systems (CNS). This results in an increase in the synaptic concentration of the neurotransmitter acetylcholine, overstimulation of cholinergic receptors and disorder of numerous body functions up to death. The standard treatment of OP poisoning includes a combination of a muscarinic antagonist and an AChE reactivator (oxime). However, these oximes can not cross the blood-brain barrier (BBB) sufficiently. Therefore, new strategies are needed to transport oximes over the BBB. METHODOLOGY/PRINCIPAL FINDINGS: In this study, we combined different oximes (obidoxime dichloride and two different HI 6 salts, HI 6 dichloride monohydrate and HI 6 dimethanesulfonate) with human serum albumin nanoparticles and could show an oxime transport over an in vitro BBB model. In general, the nanoparticulate transported oximes achieved a better reactivation of OP-inhibited AChE than free oximes. CONCLUSIONS/SIGNIFICANCE: With these nanoparticles, for the first time, a tool exists that could enable a transport of oximes over the BBB. This is very important for survival after severe OP intoxication. Therefore, these nanoparticulate formulations are promising formulations for the treatment of the peripheral and the CNS after OP poisoning. Public Library of Science 2010-12-03 /pmc/articles/PMC2997055/ /pubmed/21151975 http://dx.doi.org/10.1371/journal.pone.0014213 Text en Wagner et al. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited. |
spellingShingle | Research Article Wagner, Sylvia Kufleitner, Jürgen Zensi, Anja Dadparvar, Miriam Wien, Sascha Bungert, Judith Vogel, Tikva Worek, Franz Kreuter, Jörg von Briesen, Hagen Nanoparticulate Transport of Oximes over an In Vitro Blood-Brain Barrier Model |
title | Nanoparticulate Transport of Oximes over an In Vitro Blood-Brain Barrier Model |
title_full | Nanoparticulate Transport of Oximes over an In Vitro Blood-Brain Barrier Model |
title_fullStr | Nanoparticulate Transport of Oximes over an In Vitro Blood-Brain Barrier Model |
title_full_unstemmed | Nanoparticulate Transport of Oximes over an In Vitro Blood-Brain Barrier Model |
title_short | Nanoparticulate Transport of Oximes over an In Vitro Blood-Brain Barrier Model |
title_sort | nanoparticulate transport of oximes over an in vitro blood-brain barrier model |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2997055/ https://www.ncbi.nlm.nih.gov/pubmed/21151975 http://dx.doi.org/10.1371/journal.pone.0014213 |
work_keys_str_mv | AT wagnersylvia nanoparticulatetransportofoximesoveraninvitrobloodbrainbarriermodel AT kufleitnerjurgen nanoparticulatetransportofoximesoveraninvitrobloodbrainbarriermodel AT zensianja nanoparticulatetransportofoximesoveraninvitrobloodbrainbarriermodel AT dadparvarmiriam nanoparticulatetransportofoximesoveraninvitrobloodbrainbarriermodel AT wiensascha nanoparticulatetransportofoximesoveraninvitrobloodbrainbarriermodel AT bungertjudith nanoparticulatetransportofoximesoveraninvitrobloodbrainbarriermodel AT vogeltikva nanoparticulatetransportofoximesoveraninvitrobloodbrainbarriermodel AT worekfranz nanoparticulatetransportofoximesoveraninvitrobloodbrainbarriermodel AT kreuterjorg nanoparticulatetransportofoximesoveraninvitrobloodbrainbarriermodel AT vonbriesenhagen nanoparticulatetransportofoximesoveraninvitrobloodbrainbarriermodel |